Pfizer Inc. $PFE Shares Sold by One Capital Management LLC

One Capital Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 90.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,812 shares of the biopharmaceutical company’s stock after selling 355,025 shares during the quarter. One Capital Management LLC’s holdings in Pfizer were worth $892,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. United Bank lifted its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Sei Investments Co. lifted its holdings in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.37 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.08 and a twelve month high of $28.75. The company has a market capitalization of $144.57 billion, a price-to-earnings ratio of 19.36 and a beta of 0.34. The firm has a 50-day moving average of $26.68 and a two-hundred day moving average of $26.29.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm earned $0.92 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PFE shares. Royal Bank Of Canada reissued an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. Wolfe Research reissued an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.82.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology pipeline drew renewed optimism after ASCO 2026 data showed encouraging Phase 3 results for BRAFTOVI in metastatic colorectal cancer and TALZENNA in prostate cancer, reinforcing the company’s long-term growth story. Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
• Positive Sentiment: Jefferies reiterated a buy rating on Pfizer, and another report highlighted Pfizer as undervalued, which may help support sentiment around the stock’s current valuation. Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
• Positive Sentiment: Pfizer also received coverage suggesting its obesity and oncology pipeline could deliver multiple catalysts in 2026, keeping investors focused on upcoming data readouts and regulatory events. Pfizer’s Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Neutral Sentiment: Pfizer presented at the Jefferies Global Healthcare Conference, but the transcript appears to be mainly a routine investor update rather than a major new announcement. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Pfizer also announced updates on its ODEN ulcerative colitis study and completed a bevacizumab biosimilar safety study in Japan, both of which are incremental pipeline updates rather than immediate stock-moving breakthroughs. Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis
• Negative Sentiment: Some articles continue to frame Pfizer as a high-yield stock facing patent-cliff concerns and competitive comparisons with peers like Bristol Myers and Merck, which may weigh on sentiment despite the company’s pipeline progress. Bristol Myers vs. Pfizer: Which High-Yield Dividend Stock Wins Now?

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.